Citigroup Cuts GSK (LON:GSK) Price Target to GBX 2,100

GSK (LON:GSK) had its target price cut by Citigroup from GBX 2,250 to GBX 2,100 in a research report report published on Wednesday morning,Digital Look reports. They currently have a neutral rating on the stock.

A number of other brokerages have also issued reports on GSK. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research report on Tuesday, April 14th. Shore Capital Group restated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Berenberg Bank restated a “hold” rating and set a GBX 2,000 price objective on shares of GSK in a report on Thursday, March 26th. UBS Group reaffirmed a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,900 target price on shares of GSK in a research note on Tuesday, April 28th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, GSK presently has a consensus rating of “Hold” and an average target price of GBX 2,034.29.

GSK Stock Down 1.6%

GSK stock opened at GBX 1,843 on Wednesday. The stock has a market capitalization of £73.57 billion, a price-to-earnings ratio of 12.97, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30. The company has a 50-day moving average of GBX 2,063.58 and a two-hundred day moving average of GBX 1,932.45. GSK has a 52-week low of GBX 1,288.61 and a 52-week high of GBX 2,282. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The business had revenue of GBX 762.90 billion during the quarter. As a group, equities research analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Activity at GSK

In related news, insider Jonathan Symonds acquired 5,000 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was acquired at an average cost of GBX 1,951 per share, for a total transaction of £97,550. Also, insider Anne Beal acquired 196 shares of GSK stock in a transaction that occurred on Friday, March 20th. The shares were purchased at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Insiders bought 12,952 shares of company stock valued at $26,850,952 in the last 90 days. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.